Home/Filings/4/0001493152-23-023815
4//SEC Filing

Harvey Sandler Revocable Trust 4

Accession 0001493152-23-023815

CIK 0001712762other

Filed

Jul 5, 8:00 PM ET

Accepted

Jul 6, 4:15 PM ET

Size

11.9 KB

Accession

0001493152-23-023815

Insider Transaction Report

Form 4
Period: 2023-01-01
Rubin Gary D
Director10% Owner
Transactions
  • Award

    Common Stock

    2023-01-01$2.28/sh+8,227$18,75859,817 total
  • Award

    Common Stock

    2023-04-15$1.89/sh+9,920$18,74969,737 total
  • Award

    Common Stock

    2023-07-01$1.83/sh+10,245$18,74879,982 total
Holdings
  • Common Stock

    (indirect: By Trust)
    1,584,144
Transactions
  • Award

    Common Stock

    2023-07-01$1.83/sh+10,245$18,74879,982 total
  • Award

    Common Stock

    2023-01-01$2.28/sh+8,227$18,75859,817 total
  • Award

    Common Stock

    2023-04-15$1.89/sh+9,920$18,74969,737 total
Holdings
  • Common Stock

    (indirect: By Trust)
    1,584,144
Footnotes (4)
  • [F1]Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Mr. Rubin of 8,227 restricted shares of common stock, par value $0.007 (the "Common Stock"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
  • [F2]Represents a grant from the Issuer to Mr. Rubin of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Mr. Rubin continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
  • [F3]Represents a grant from the Issuer to Mr. Rubin of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
  • [F4]Represents shares of Common Stock owned directly by the Harvey Sandler Revocable Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Mr. Rubin, as co-trustee of the Trust, which indirect ownership was previously reported on a Form 4 filed by Mr. Rubin and the Trust on October 21, 2022. Mr. Rubin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Documents

1 file

Issuer

bioAffinity Technologies, Inc.

CIK 0001712762

Entity typeother
IncorporatedFL

Related Parties

1
  • filerCIK 0001323253

Filing Metadata

Form type
4
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 4:15 PM ET
Size
11.9 KB